Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax(®) compared with Turbuhaler(®) in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

OBJECTIVE: The objective of this study was to estimate the economic impact of the introduction of DuoResp(®) Spiromax(®), budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Darbà, Josep, Ramírez, Gabriela, García-Rivero, Juan L, Mayoralas, Sagrario, Pascual, José Francisco, Vargas, Diego, Bijedic, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312689/
https://www.ncbi.nlm.nih.gov/pubmed/28228660
http://dx.doi.org/10.2147/CEOR.S125301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312689/
https://www.ncbi.nlm.nih.gov/pubmed/28228660
http://dx.doi.org/10.2147/CEOR.S125301

Ejemplares similares